Efficacy of an anti-TSLP monoclonal antibody in the management of chronic bronchial disease induced by bronchiolitis obliterans syndrome in allogeneic hematopoietic stem cells transplantation recipients.
The IMMUNO-BOS study is investigating a new medication, Tezspire, for adults who have developed a serious lung condition known as Bronchiolitis Obliterans Syndrome (BOS) after a stem cell transplant. BOS can cause severe breathing difficulties. The main goal is to find out if Tezspire can lower the number of times these patients experience severe lung flare-ups that require them to be admitted to hospital or take strong medicines like antibiotics or steroids. Researchers will compare how often these breathing problems happen in the year before starting Tezspire to the year while taking it. This is a Phase II study, meaning it's still in the early stages of showing if the treatment works and is safe.
At a glance
What is this study about?
This study, called IMMUNO-BOS, is looking into a new medicine called Tezspire. It's for people who have a specific and serious lung problem called Bronchiolitis Obliterans Syndrome, or BOS. This condition can sometimes develop in individuals who have had a special type of transplant called an allogeneic stem cell transplant. BOS causes the small airways in the lungs to become damaged and narrowed, leading to significant breathing difficulties and frequent flare-ups.
The main aim of the study is to see if Tezspire can help reduce these severe breathing flare-ups. Researchers want to know if, after taking Tezspire for a year, people have fewer episodes of severe lung symptoms that require them to go to hospital or take strong medications like antibiotics or steroids. They will compare how many of these episodes happened in the year before treatment with how many happen during the year of treatment.
This is a 'Phase II' study, which means it's an early but important step in testing a new medicine. It helps doctors understand if the treatment shows promise and is reasonably safe before larger studies are done. The information gathered will help us learn more about how Tezspire affects people with BOS and whether it could be a helpful new treatment option in the future. The study will also look at whether the medicine improves breathing, reduces the need for other medications, and changes certain markers in the blood and breath.
Key takeaways
- This study is for adults with a serious lung condition called BOS after a stem cell transplant.
- It tests a new medicine called Tezspire to see if it reduces severe breathing problems.
- Participation involves regular clinic visits, lung function tests, and blood tests over more than a year.
- It's a Phase II study, an early step in testing the new treatment.
- Potential benefits include access to a new treatment; potential risks include side effects.
Who may be eligible?
To be considered for this study, you must be at least 18 years old. There's no upper age limit, so adults of any age can potentially take part.
Both men and women are welcome to participate in this study. The study aims to include a diverse group of patients to ensure the findings are as widely applicable as possible.
Beyond these basic requirements, you would need to have been diagnosed with Bronchiolitis Obliterans Syndrome (BOS) after an allogeneic stem cell transplant. A doctor involved in the study would need to confirm that your specific medical situation meets all the other detailed study requirements.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you been diagnosed with Bronchiolitis Obliterans Syndrome (BOS)?
- Did your BOS develop after an allogeneic stem cell transplant?
- Are you able to attend regular clinic visits for check-ups and tests?
What does participation involve?
If you decide to take part in this study, you would receive the study medication, Tezspire, as an injection using a pre-filled syringe. You'd likely be taught how to administer this yourself or have it done for you by a healthcare professional at regular intervals. Over a period of one year, you would have several visits to the clinic for various check-ups. These visits would involve taking measurements of your breathing and lung function, using special machines to see how well your lungs are working. You would also fill out questionnaires about your breathing symptoms and overall health, and have blood tests done. Researchers might also collect samples of your breath for special analysis. After the treatment period, there would be follow-up appointments to monitor your health. The total duration of your active involvement in the study, including treatment and follow-up, would be more than 12 months.
Potential risks and benefits
Locations (1)
- —UnverifiedFrance
Common questions
What is Bronchiolitis Obliterans Syndrome (BOS)?
BOS is a serious lung condition that can happen after a stem cell transplant, where the small airways in your lungs become narrowed, making it hard to breathe.
What is Tezspire?
Tezspire is the new medicine being tested in this study. It's a type of antibody designed to help with certain inflammation processes that might play a role in lung conditions.
How is Tezspire given?
Tezspire is given as an injection using a pre-filled syringe.
What is a 'Phase II' study?
A Phase II study is an early stage of clinical research. It's designed to see if a new treatment is effective and safe enough to continue with larger studies.
Will I receive different treatment if I don't join?
No, your decision to join or not join the study will not affect the standard medical care you receive for your condition.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.